Primary systemic therapy of breast cancer

Irina Sachelarie, Michael L. Grossbard, Manjeet Chadha, Sheldon M. Feldman, Munir Ghesani, Ronald H. Blum

Research output: Contribution to journalReview article

111 Citations (Scopus)

Abstract

Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The multitude of clinical trials using PST in breast cancer patients has not proven the fundamental hypotheses of improved overall survival and disease-free survival that drove the investigation of PST. The other potential advantages of PST, which include increasing the rate of breast-conserving surgery and predicting outcome to a particular chemotherapy regimen, are also not conclusively established. We examined the published literature on PST for breast cancer and predominantly focused our review on data from large, randomized clinical trials comparing primary systemic chemotherapy with adjuvant chemotherapy, different primary systemic chemotherapy regimens, primary systemic chemotherapy with hormonal therapy, and different preoperative hormonal therapies. Although the optimal neoadjuvant chemotherapy regimen has not been established, a combination of four cycles of an anthracycline followed by four cycles of a taxane appears to produce the highest pCR rate (22%-31%). In patients with HER-2-positive breast cancer, concurrent use of neoadjuvant trastuzumab with an anthracycline-taxane combination has produced provocative results that require further confirmatory studies. Preoperative hormonal therapy is associated with low pCR rates and should be reserved for patients who are poor candidates for systemic chemotherapy. The optimal management of patients with residual disease after the administration of maximum neoadjuvant therapy remains to be defined. The surgical approach, including the role of sentinel node biopsy and delivery of radiation therapy after PST in breast cancer patients, is evolving. Ongoing clinical trials will help identify the subset of patients who would most benefit from the use of PST, establish the most effective PST regimen, and determine the optimal multidisciplinary approach in the management of breast cancer.

Original languageEnglish (US)
Pages (from-to)574-589
Number of pages16
JournalOncologist
Volume11
Issue number6
DOIs
StatePublished - Jul 5 2006
Externally publishedYes

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Neoadjuvant Therapy
Anthracyclines
Clinical Trials
Segmental Mastectomy
Adjuvant Chemotherapy
Disease-Free Survival
Radiotherapy
Randomized Controlled Trials
Biopsy
Survival
Neoplasms

Keywords

  • Anthracycline
  • Pathologic complete response
  • Primary systemic therapy
  • Taxane

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Sachelarie, I., Grossbard, M. L., Chadha, M., Feldman, S. M., Ghesani, M., & Blum, R. H. (2006). Primary systemic therapy of breast cancer. Oncologist, 11(6), 574-589. https://doi.org/10.1634/theoncologist.11-6-574

Primary systemic therapy of breast cancer. / Sachelarie, Irina; Grossbard, Michael L.; Chadha, Manjeet; Feldman, Sheldon M.; Ghesani, Munir; Blum, Ronald H.

In: Oncologist, Vol. 11, No. 6, 05.07.2006, p. 574-589.

Research output: Contribution to journalReview article

Sachelarie, I, Grossbard, ML, Chadha, M, Feldman, SM, Ghesani, M & Blum, RH 2006, 'Primary systemic therapy of breast cancer', Oncologist, vol. 11, no. 6, pp. 574-589. https://doi.org/10.1634/theoncologist.11-6-574
Sachelarie I, Grossbard ML, Chadha M, Feldman SM, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006 Jul 5;11(6):574-589. https://doi.org/10.1634/theoncologist.11-6-574
Sachelarie, Irina ; Grossbard, Michael L. ; Chadha, Manjeet ; Feldman, Sheldon M. ; Ghesani, Munir ; Blum, Ronald H. / Primary systemic therapy of breast cancer. In: Oncologist. 2006 ; Vol. 11, No. 6. pp. 574-589.
@article{f2cc56124d7c4c219f30fccce7aeca4c,
title = "Primary systemic therapy of breast cancer",
abstract = "Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The multitude of clinical trials using PST in breast cancer patients has not proven the fundamental hypotheses of improved overall survival and disease-free survival that drove the investigation of PST. The other potential advantages of PST, which include increasing the rate of breast-conserving surgery and predicting outcome to a particular chemotherapy regimen, are also not conclusively established. We examined the published literature on PST for breast cancer and predominantly focused our review on data from large, randomized clinical trials comparing primary systemic chemotherapy with adjuvant chemotherapy, different primary systemic chemotherapy regimens, primary systemic chemotherapy with hormonal therapy, and different preoperative hormonal therapies. Although the optimal neoadjuvant chemotherapy regimen has not been established, a combination of four cycles of an anthracycline followed by four cycles of a taxane appears to produce the highest pCR rate (22{\%}-31{\%}). In patients with HER-2-positive breast cancer, concurrent use of neoadjuvant trastuzumab with an anthracycline-taxane combination has produced provocative results that require further confirmatory studies. Preoperative hormonal therapy is associated with low pCR rates and should be reserved for patients who are poor candidates for systemic chemotherapy. The optimal management of patients with residual disease after the administration of maximum neoadjuvant therapy remains to be defined. The surgical approach, including the role of sentinel node biopsy and delivery of radiation therapy after PST in breast cancer patients, is evolving. Ongoing clinical trials will help identify the subset of patients who would most benefit from the use of PST, establish the most effective PST regimen, and determine the optimal multidisciplinary approach in the management of breast cancer.",
keywords = "Anthracycline, Pathologic complete response, Primary systemic therapy, Taxane",
author = "Irina Sachelarie and Grossbard, {Michael L.} and Manjeet Chadha and Feldman, {Sheldon M.} and Munir Ghesani and Blum, {Ronald H.}",
year = "2006",
month = "7",
day = "5",
doi = "10.1634/theoncologist.11-6-574",
language = "English (US)",
volume = "11",
pages = "574--589",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - Primary systemic therapy of breast cancer

AU - Sachelarie, Irina

AU - Grossbard, Michael L.

AU - Chadha, Manjeet

AU - Feldman, Sheldon M.

AU - Ghesani, Munir

AU - Blum, Ronald H.

PY - 2006/7/5

Y1 - 2006/7/5

N2 - Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The multitude of clinical trials using PST in breast cancer patients has not proven the fundamental hypotheses of improved overall survival and disease-free survival that drove the investigation of PST. The other potential advantages of PST, which include increasing the rate of breast-conserving surgery and predicting outcome to a particular chemotherapy regimen, are also not conclusively established. We examined the published literature on PST for breast cancer and predominantly focused our review on data from large, randomized clinical trials comparing primary systemic chemotherapy with adjuvant chemotherapy, different primary systemic chemotherapy regimens, primary systemic chemotherapy with hormonal therapy, and different preoperative hormonal therapies. Although the optimal neoadjuvant chemotherapy regimen has not been established, a combination of four cycles of an anthracycline followed by four cycles of a taxane appears to produce the highest pCR rate (22%-31%). In patients with HER-2-positive breast cancer, concurrent use of neoadjuvant trastuzumab with an anthracycline-taxane combination has produced provocative results that require further confirmatory studies. Preoperative hormonal therapy is associated with low pCR rates and should be reserved for patients who are poor candidates for systemic chemotherapy. The optimal management of patients with residual disease after the administration of maximum neoadjuvant therapy remains to be defined. The surgical approach, including the role of sentinel node biopsy and delivery of radiation therapy after PST in breast cancer patients, is evolving. Ongoing clinical trials will help identify the subset of patients who would most benefit from the use of PST, establish the most effective PST regimen, and determine the optimal multidisciplinary approach in the management of breast cancer.

AB - Primary systemic therapy (PST) or neoadjuvant therapy is used in nonmetastatic breast cancer to treat systemic disease earlier, decrease tumor bulk ideally to a complete pathological response (pCR), and reduce the extent of surgery. The multitude of clinical trials using PST in breast cancer patients has not proven the fundamental hypotheses of improved overall survival and disease-free survival that drove the investigation of PST. The other potential advantages of PST, which include increasing the rate of breast-conserving surgery and predicting outcome to a particular chemotherapy regimen, are also not conclusively established. We examined the published literature on PST for breast cancer and predominantly focused our review on data from large, randomized clinical trials comparing primary systemic chemotherapy with adjuvant chemotherapy, different primary systemic chemotherapy regimens, primary systemic chemotherapy with hormonal therapy, and different preoperative hormonal therapies. Although the optimal neoadjuvant chemotherapy regimen has not been established, a combination of four cycles of an anthracycline followed by four cycles of a taxane appears to produce the highest pCR rate (22%-31%). In patients with HER-2-positive breast cancer, concurrent use of neoadjuvant trastuzumab with an anthracycline-taxane combination has produced provocative results that require further confirmatory studies. Preoperative hormonal therapy is associated with low pCR rates and should be reserved for patients who are poor candidates for systemic chemotherapy. The optimal management of patients with residual disease after the administration of maximum neoadjuvant therapy remains to be defined. The surgical approach, including the role of sentinel node biopsy and delivery of radiation therapy after PST in breast cancer patients, is evolving. Ongoing clinical trials will help identify the subset of patients who would most benefit from the use of PST, establish the most effective PST regimen, and determine the optimal multidisciplinary approach in the management of breast cancer.

KW - Anthracycline

KW - Pathologic complete response

KW - Primary systemic therapy

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=33745670605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745670605&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.11-6-574

DO - 10.1634/theoncologist.11-6-574

M3 - Review article

C2 - 16794237

AN - SCOPUS:33745670605

VL - 11

SP - 574

EP - 589

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 6

ER -